May 12, 2014 / 11:46 AM / 4 years ago

REFILE-Tesaro's experimental drug meets main goal in final trial

(Refiles to fix spelling of “experimental” in paragraph 1)

May 12 (Reuters) - Tesaro Inc said its experimental drug for the prevention of chemotherapy-induced nausea and vomiting met the main goal in a third late-stage trial.

Tesaro shares jumped nearly 15 percent to $27.50 in premarket trading.

The company had said in December the drug, rolapitant, was also found to be effective for use in the same indication in two other late-stage trials. (Reporting by Natalie Grover in Bangalore; Editing by Joyjeet Das)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below